Syndopa CR 250: Levodopa-Carbidopa Uses, Controlled-Release Action, and Side Effects
Written by Dr. Zack Ferris in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Aug 29 2026
Syndopa CR 250 is a prescription medicine used to control movement symptoms of Parkinson’s disease. Despite the “250” in the name, current Indian medicine listings identify the controlled-release tablet as containing 200 mg of levodopa plus 50 mg of carbidopa, for a combined 250 mg of active ingredients. Levodopa enters the brain and is converted into dopamine, while carbidopa helps more levodopa reach the brain instead of being broken down elsewhere in the body. The CR formulation releases the medicines more gradually than a conventional immediate-release tablet, which can help provide longer symptom coverage in selected patients. However, controlled release does not mean instant relief or perfectly steady symptom control, and the medicine can still cause dyskinesia, nausea, dizziness, hallucinations, sleepiness, and blood-pressure changes. This guide explains what Syndopa CR 250 is used for, how its controlled-release action works, how food can affect levodopa, and the safety issues patients and caregivers should know.
What Is Syndopa CR 250 Used For?
Syndopa CR 250 is used for the symptomatic treatment of Parkinson’s disease and related parkinsonian movement disorders. Its purpose is to improve problems caused by reduced dopamine activity in the brain, particularly slowness of movement, muscle stiffness, and, in many patients, tremor.
Levodopa remains one of the most effective medicines for Parkinson’s movement symptoms. Parkinson’s Foundation guidance notes that carbidopa-levodopa particularly improves bradykinesia, meaning slowness of movement, and rigidity, although its effect on tremor varies between individuals.
The Parkinson’s Foundation guide to levodopa treatment also emphasizes that different carbidopa-levodopa preparations are not automatically interchangeable. Immediate-release, controlled-release, and newer extended-release formulations have different strengths and release characteristics.
Why combine levodopa with carbidopa? (H3)
Parkinson’s disease involves loss of dopamine-producing neurons in areas of the brain involved in movement.
Dopamine itself cannot effectively cross the blood-brain barrier when taken as a medicine. Levodopa can cross this barrier and is converted into dopamine after it reaches the brain.
The problem is that levodopa can also be converted into dopamine before reaching the brain. Carbidopa blocks much of this peripheral conversion, allowing more levodopa to reach its intended destination while reducing some peripheral side effects such as nausea. Official extended-release carbidopa-levodopa labeling explains that carbidopa increases the amount of levodopa available for transport into the central nervous system.
Does Syndopa CR cure Parkinson’s disease?
No. Syndopa CR treats symptoms; it does not cure Parkinson’s disease or replace dopamine-producing brain cells.
Parkinson’s is progressive, so medication schedules often need adjustment as symptoms, motor fluctuations, swallowing, digestion, and treatment response change over time.
Syndopa CR 250 at a glance
Feature | What to know |
Active ingredients | Levodopa 200 mg + carbidopa 50 mg in current Indian listings |
Medicine type | Anti-Parkinson medicine |
Formulation | Controlled-release tablet |
Main purpose | Improves Parkinson’s movement symptoms |
Levodopa action | Crosses into the brain and is converted to dopamine |
Carbidopa action | Reduces levodopa breakdown outside the brain |
Does it cure Parkinson’s? | No; it provides symptomatic treatment |
Can it be swapped directly with immediate-release levodopa? | Not without medical guidance because absorption and release differ |
The “250” in Syndopa CR 250 should not be interpreted as 250 mg of levodopa. Current Indian listings identify the tablet as 200 mg levodopa plus 50 mg carbidopa, and the controlled-release formulation behaves differently from an immediate-release tablet.
How Does the Controlled-Release Action of Syndopa CR Work?
Controlled-release carbidopa-levodopa tablets release the medicines gradually as the tablet matrix erodes. Comparable 50 mg/200 mg extended-release tablets are designed to release carbidopa and levodopa over approximately four to six hours.
The goal is to produce less variation in blood levodopa concentrations than conventional immediate-release tablets.
The current extended-release carbidopa-levodopa prescribing information reports that extended-release tablets produce less fluctuation in plasma levodopa levels, although they are less bioavailable than conventional immediate-release tablets.
That lower bioavailability is important because milligram-for-milligram substitution is not necessarily appropriate.
Why might a controlled-release formulation be prescribed?
As Parkinson’s progresses, some people develop motor fluctuations.
These can include:
wearing off: symptoms return before the next dose;
delayed “on”: a dose takes longer than expected to begin working;
“off” periods: movement becomes slower, stiffer, or more difficult;
peak-dose dyskinesia: involuntary movements occur when levodopa effects are strongest; and
on-off fluctuations: mobility can change unpredictably.
A longer-acting formulation may be used to provide more prolonged coverage or reduce how frequently tablets need to be taken.
However, controlled-release levodopa is not guaranteed to eliminate off time. Clinical trials of older controlled-release formulations found that patients with moderate-to-severe motor fluctuations did not have a quantitatively significant reduction in off time compared with conventional carbidopa-levodopa, although global improvement ratings were better in some patients.
Does CR work more slowly than immediate-release levodopa?
It can.
In pharmacokinetic studies, the average time to peak levodopa concentration after a 50/200 mg extended-release tablet was about two hours, compared with approximately 30 minutes for a conventional tablet.
That is one reason a controlled-release tablet should not automatically be used as a rapid “rescue” dose when symptoms suddenly return.
How Should Syndopa CR 250 Be Taken, and Does Food Matter?
Syndopa CR should be taken according to the neurologist’s prescribed schedule rather than adjusted according to how you feel at a particular moment. Controlled-release carbidopa-levodopa dosing must be individually titrated because response varies substantially between patients.
Comparable extended-release product labeling specifically advises that the tablet should not be chewed or crushed because doing so interferes with the controlled-release system.
Protein can interfere with levodopa absorption
Levodopa uses transport pathways that are also used by certain amino acids from dietary protein.
As a result, a high-protein meal may delay levodopa absorption or reduce how much medicine becomes available in some patients. The effect is often most noticeable in people who already experience motor fluctuations.
The Parkinson’s Foundation guidance on food and levodopa advises that some patients may benefit from taking carbidopa-levodopa 30–60 minutes before food or one to two hours after a meal, although patients who develop nausea may need individualized advice.
This does not mean people with Parkinson’s should eliminate protein. Protein is nutritionally important, particularly in older adults who may already be vulnerable to weight loss and muscle loss.
If food seems to affect medication response, discuss meal timing or protein distribution with the treating neurologist or a dietitian familiar with Parkinson’s disease.
Iron can also interact with levodopa
Iron supplements and multivitamins containing iron may bind with levodopa and carbidopa and reduce their bioavailability.
If iron has been prescribed because of deficiency, do not stop it independently. Ask the clinician or pharmacist whether the timing of iron and Syndopa should be separated.
What if a dose is missed?
Do not double the next dose unless specifically instructed.
Parkinson’s medication schedules can be highly individualized, particularly in patients with motor fluctuations, so missed-dose advice should follow the prescriber’s instructions rather than a universal rule.
Also avoid adding an extra immediate-release levodopa tablet on your own. Comparable CR labeling advises patients not to add other carbidopa-levodopa preparations without consulting the prescriber.
What Are the Side Effects of Syndopa CR 250?
Common and clinically important effects of controlled-release carbidopa-levodopa include involuntary movements, nausea, hallucinations, confusion, dizziness, and blood-pressure changes. The likelihood and severity depend partly on levodopa exposure, disease stage, age, and other medicines.
In controlled trials of extended-release carbidopa-levodopa, dyskinesia was reported more frequently than nausea, hallucinations, confusion, dizziness, and several other adverse effects.
Dyskinesia and extra movements
Dyskinesias are involuntary movements that can include writhing, twisting, fidgeting, or jerking.
They are related to dopaminergic treatment and often occur when the levodopa effect is relatively strong.
Extended-release product labeling notes that new or worsening dyskinesia may require dose adjustment.
Do not reduce the medication yourself. The neurologist may alter individual dose sizes, timing, formulation, or other Parkinson’s medicines depending on the pattern.
Nausea, dizziness, and low blood pressure
Levodopa can cause nausea, particularly when treatment is started or doses are changed.
Orthostatic hypotension is another concern. This means blood pressure falls when standing, potentially producing lightheadedness, weakness, blurred vision, or fainting.
The risk may increase when carbidopa-levodopa is combined with blood-pressure-lowering medicines. Official labeling notes that antihypertensive doses sometimes need review after carbidopa-levodopa therapy is introduced.
Hallucinations and confusion
Hallucinations can occur with dopaminergic medicines, particularly in older patients or people with more advanced Parkinson’s disease.
They may involve seeing or hearing things that are not present and can occur with confusion, vivid dreams, agitation, delusions, or other behavioral changes.
New hallucinations should be reported rather than dismissed as an inevitable part of Parkinson’s.
Sleepiness and sudden sleep episodes
Carbidopa-levodopa can cause significant daytime sleepiness, and rare patients have reported suddenly falling asleep during everyday activities without adequate warning.
Road accidents have occurred in association with sudden sleep onset. Patients who experience significant daytime sleepiness or sudden sleep episodes should not drive or undertake hazardous activities until the situation has been medically reviewed.
Syndopa CR side effects and what they may mean
Effect | What you may notice | Practical response |
Dyskinesia | Twisting, writhing, jerking, or other involuntary movements | Tell the neurologist; dose or timing may need adjustment |
Nausea | Queasiness or vomiting | Discuss persistent symptoms; food timing sometimes needs adjustment |
Orthostatic hypotension | Dizziness or faintness after standing | Rise carefully and report repeated episodes |
Hallucinations | Seeing or hearing things that are not present | Inform the clinician, especially if new or worsening |
Confusion | Disorientation or unusual behavior | Medical review is appropriate |
Sleepiness | Excessive daytime drowsiness | Avoid driving if significantly sleepy |
Sudden sleep onset | Falling asleep without adequate warning | Stop driving and seek prompt medication review |
Wearing off | Parkinson’s symptoms return before the next dose | Keep a symptom-and-dose record and discuss it with the neurologist |
Which Medicines and Health Conditions Need Extra Caution?
Syndopa CR can interact with medicines that influence dopamine, blood pressure, or levodopa absorption.
Parkinson’s patients often take several medicines, so medication reconciliation is particularly important.
Medicines that can reduce levodopa effectiveness
Some dopamine-blocking medicines can work against levodopa.
Comparable prescribing information lists dopamine D2 receptor antagonists, including some antipsychotic medicines, as drugs that may reduce levodopa’s therapeutic effect. It also identifies isoniazid and some other medicines as possible causes of reduced response.
This does not mean these medicines can never be used. It means the combination needs clinical review.
Metoclopramide is another example. Although it can speed gastric emptying, it blocks dopamine receptors and may worsen Parkinson’s disease control.
Blood-pressure medicines
Because levodopa can contribute to orthostatic hypotension, combining it with antihypertensive medicines can increase dizziness or fainting in some people.
Patients taking drugs for hypertension or heart disease should report new postural dizziness after a Syndopa dose or schedule change.
Certain antidepressants and MAO inhibitors
Some antidepressants require special caution.
Older non-selective monoamine oxidase inhibitors can interact dangerously with levodopa-containing therapy, while specific Parkinson’s medicines that affect monoamine oxidase have their own interaction considerations.
Always provide the neurologist and pharmacist with a complete list of antidepressants, psychiatric medicines, and supplements rather than assuming an OTC or herbal product is irrelevant.
Other health conditions
Extra caution may be appropriate in patients with severe cardiovascular or lung disease, kidney or liver disease, endocrine disorders, previous peptic-ulcer bleeding, glaucoma, or significant psychiatric illness.
Pregnancy and breastfeeding also require specialist discussion because available human safety information is limited and levodopa has been detected in human milk.
How Does Syndopa CR Fit Into Long-Term Parkinson’s Treatment?
Syndopa CR is one formulation within a broader Parkinson’s treatment plan. The right levodopa preparation depends on when symptoms occur, how long each dose lasts, whether dyskinesia develops, and how predictable absorption is.
Some patients use only immediate-release carbidopa-levodopa. Others may receive a controlled- or extended-release preparation at selected times, while people with more complex fluctuations may need other medicines or advanced therapies.
Keeping a medication diary can be useful
When treatment becomes complicated, it can help to record:
medication time;
meal time;
when the patient becomes “on”;
when symptoms begin to wear off;
periods of dyskinesia;
freezing or immobility;
hallucinations;
dizziness; and
daytime sleepiness.
Patterns can help the neurologist determine whether the problem relates to dose size, timing, absorption, formulation, disease progression, or another medicine.
The controlled-release formulation should not be judged only by whether it seems to “last longer.” The clinically important question is whether the entire medication schedule gives acceptable mobility without excessive dyskinesia or other adverse effects.
Safety: When Should You Contact a Doctor or Seek Urgent Help?
Contact the treating neurologist if Parkinson’s symptoms begin wearing off much earlier than usual, doses become unpredictable, dyskinesia becomes troublesome, hallucinations develop, or repeated dizziness or fainting occurs.
New compulsive behaviors also deserve medical attention. Dopaminergic medicines have been associated with intense gambling urges, increased sexual urges, uncontrolled spending, binge eating, and other impulse-control problems. Patients may not always recognize these changes themselves, so caregivers can play an important role in noticing them.
Do not abruptly stop Syndopa CR unless a clinician specifically directs you to do so.
The official warning on abrupt carbidopa-levodopa withdrawal describes a rare but potentially life-threatening syndrome resembling neuroleptic malignant syndrome after sudden dose reductions or discontinuation. It can involve high fever, severe rigidity, altered consciousness, autonomic instability, and laboratory abnormalities.
Seek urgent medical care for severe fever with marked stiffness or confusion, loss of consciousness, severe breathing difficulty, chest pain with significant symptoms, or another rapidly worsening reaction.
Sudden sleep episodes are also a major safety concern. A patient who unexpectedly falls asleep while driving, eating, talking, or performing another active task should stop driving and contact the treating clinician promptly.
Conclusion
Syndopa CR 250 combines 200 mg of levodopa with 50 mg of carbidopa in a controlled-release formulation designed to provide more gradual levodopa delivery for Parkinson’s symptoms. Levodopa replaces an important dopamine precursor, while carbidopa allows more of it to reach the brain.
Controlled release may provide longer or smoother coverage for some patients, but absorption can still vary, particularly around high-protein meals, and side effects such as dyskinesia, nausea, hallucinations, dizziness, and sleepiness remain possible. Because Parkinson’s treatment is highly individualized, do not crush the CR tablet, change the dose, add another levodopa product, or stop Syndopa abruptly without guidance from the treating neurologist.
Frequently Asked Questions
1. What does Syndopa CR 250 contain?
Current Indian medicine listings identify Syndopa CR 250 as containing 200 mg of levodopa plus 50 mg of carbidopa. The “250” reflects the combined amount rather than 250 mg of levodopa alone. Always check the actual strength printed on your prescribed pack.
2. Is Syndopa CR 250 the same as regular Syndopa?
Not necessarily. CR means controlled release, so the medicines are released more gradually than in conventional immediate-release tablets. Absorption, onset, duration, and dose requirements can therefore differ. Do not substitute one formulation for another without instructions from the neurologist or pharmacist.
3. How long does Syndopa CR take to start working?
Controlled-release levodopa generally reaches peak blood concentrations more slowly than immediate-release levodopa. Comparable 50/200 mg extended-release tablets reached peak levodopa levels at about two hours on average in one pharmacokinetic study. Individual onset can vary considerably.
4. Should Syndopa CR be taken before or after food?
Food timing may matter, particularly with high-protein meals, because amino acids can interfere with levodopa absorption. Some patients are advised to take levodopa before meals, but nausea or nutritional needs may change that recommendation. Ask your neurologist for individualized timing advice.
5. Can Syndopa CR cause involuntary movements?
Yes. Dyskinesia is a recognized effect of levodopa therapy and may appear as writhing, twisting, jerking, or other uncontrolled movements. New or worsening dyskinesia may mean the levodopa regimen needs adjustment, but patients should not reduce the dose independently.
6. Can I stop Syndopa CR if it causes side effects?
Do not stop it suddenly without medical guidance. Abrupt reduction or withdrawal of levodopa-containing treatment has rarely been linked with a serious syndrome involving high fever, severe rigidity, confusion, and autonomic instability. Contact the prescriber promptly if side effects are causing concern.
Comments